Biocartis Group NV (LTS:0R72) Research & Development: €37.51 Mil (TTM As of Jun. 2023)


LTS:0R72 Biocartis Group NV LTS:0R72
14 GF Score
Price €0.30
View Full Analysis

What is Biocartis Group NV Research & Development?

Biocartis Group NV LTS:0R72 14 Research & Development is €37.51 Mil as of Jun. 2023. GuruFocus rates LTS:0R72 with a GF Score™ of 14/100.

Research & Development is the aggregate amount of research and development expenses during the year. Biocartis Group NV's Research & Development for the six months ended in Jun. 2023 was €16.39 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 was €37.51 Mil.

Biocartis Group NV  (LTS:0R72) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Biocartis Group NV Research & Development Related Terms

Biocartis Group NV Research & Development Historical Data

* Premium members only.

The historical data trend for Biocartis Group NV's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocartis Group NV Research & Development Chart

Biocartis Group NV Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.84 39.84 40.93 48.05 38.39

Biocartis Group NV Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.61 26.45 17.27 21.12 16.39
LTS:0R72
14GF Score
Biocartis Group NV LTS:0R72
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocartis Group NV Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €37.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €37.51 Mil mean?
Biocartis Group NV (LTS:0R72) has a Research & Development of €37.51 Mil as of Jun. 2023. Research and development expense is the total cost for research and development activities. View historical data on Biocartis Group NV and its competitors.
Is Biocartis Group NV's Research & Development too high?
Biocartis Group NV's current Research & Development is €37.51 Mil. Overall, Biocartis Group NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Biocartis Group NV's Research & Development compare to TMO and DHR?
Biocartis Group NV's Research & Development of €37.51 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Biocartis Group NV and its competitors. Biocartis Group NV's current Research & Development is €37.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocartis Group NV stock overvalued right now?
Biocartis Group NV (LTS:0R72) has a current Research & Development of €37.51 Mil. The current Research & Development is €37.51 Mil. Biocartis Group NV's overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Biocartis Group NV (LTS:0R72), the current Research & Development is €37.51 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biocartis Group NV Business Description

Address Generaal de Wittelaan 11 B, Mechelen, BEL, 2800
Biocartis Group NV is a commercial-stage molecular diagnostics company. It provides diagnostic solutions aimed at improving clinical practice for patients, clinicians, payers, and the industry. The firm has developed an Meet Idylla molecular diagnostic system for oncology and infectious disease segments.
14GF Score

Get the complete analysis for LTS:0R72

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.30
Price